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The Mycobacterium bovis Bacille Calmette Guérin (BCG) vaccine shows variable efficacy in protection
against adult tuberculosis (TB). Earlier, we have described a BCG mutant vaccine with a transposon inser-
tion in the gene coding for the secreted acid phosphatase SapM, which led to enhanced long-term sur-
vival of vaccinated mice challenged with TB infection. To facilitate development of this mutation as
part of a future improved live attenuated TB vaccine, we have now characterized the genome and tran-
scriptome of this sapM::Tn mutant versus parental BCG Pasteur. Furthermore, we show that the sapM::Tn
mutant had an equal low pathogenicity as WT BCG upon intravenous administration to immunocompro-
mised SCID mice, passing this important safety test. Subsequently, we investigated the clearance of this
improved vaccine strain following vaccination and found a more effective innate immune control over
the sapM::Tn vaccine bacteria as compared to WT BCG. This leads to a fast contraction of IFNc producing
Th1 and Tc1 cells after sapM::Tn BCG vaccination. These findings corroborate that a live attenuated vac-
cine that affords improved long-term survival upon TB infection can be obtained by a mutation that fur-
ther attenuates BCG. These findings suggest that an analysis of the effectiveness of innate immune control
of the vaccine bacteria could be instructive also for other live attenuated TB vaccines that are currently
under development, and encourage further studies of SapM mutation as a strategy in developing a more
protective live attenuated TB vaccine.
 2019 Elsevier Ltd. All rights reserved.1. Introduction
Today, TB remains one of the major causes of infectious disease
and death throughout the world [1]. About 10 million people
developed TB in 2017, with an estimated 1.3 million deaths.
Although new and promising anti-tubercular drugs are in or
approaching the clinic, full control over this devastating disease
will necessarily require a good, preventive anti-TB vaccine [2].
M. bovis Bacille-Calmette-Guérin (BCG) is the only licensed vaccine
today, and already in use for almost 100 years. Although BCG isprotective against TB meningitis and disseminated TB in children,
its efficacy against pulmonary TB is highly variable and not suffi-
cient for disease control [3–5].
Currently, 13 vaccine candidates are under active development
and in the process of clinical testing. Besides two live recombinant
candidates (VPM1002 and MTBVAC) which are being tested to
replace BCG as a priming vaccine, the candidates being mainly
variations of booster vaccines with recurrent key mycobacterial
antigens [2,6,7]. Several of these vaccine candidates yield enhanced
interferon c (IFNɣ)-producing cellular immunity and enhanced
control over bacterial replication in the first weeks after TB chal-
lenge in animal models. However, reports that show extended
long-term survival of vaccinated animals upon TB challenge are
much rarer. In the category of priming vaccines, it has been shown
that rBCG30 (BCG Tice overexpressing the M. tb 30-kDa major
secretory protein antigen 85B)-immunized mice survive longer
than BCG-immunized mice following TB challenge [8]. SO2 (phoP
inactivated in M. tb strain MT103), the MTBVAC (containing a dou-
ble deletion in phoP and fadD26) prototype, conferred greater effi-
cacy than BCG in a high-dose challenge, long-term survival
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observed after low-dose challenge [9]. The recombinant BCG strain
AFRO-1 (BCG1331 DureC::XpfoAG137Q, Ag85A, Ag85B and TB10.4)
affords better protection than BCG in mice following aerosol chal-
lenge with Mycobacterium tuberculosis (M.tb) [10]. Additionally,
some prime-boost vaccination strategies demonstrated improved
long-term survival of M.tb-challenged guinea pigs versus BCG
alone: BCG priming followed by the M72 recombinant protein
booster vaccine (fusion of Mtb32 and Mtb39 antigens of Mtb)
[11] and ID93 (combines four antigens belonging to families of
M.tb proteins associated with virulence (Rv2608, Rv3619,
Rv3620) or latency (Rv1813)/GLA-SE)) [12].
Earlier, we have demonstrated how a sapM transposon mutant
of M. bovis BCG, hereafter called sapM::Tn BCG, resulted in a TB
vaccine candidate that provides improved long-term survival in
mice upon both systemic and intratracheal challenge with M. tb
as compared to the parental BCG Pasteur-derived strain (hereafter
called WT BCG) [13]. We suggested that the secreted acid phos-
phatase SapM may have evolved as an important immunomodula-
tory protein of Mycobacteria. The importance of SapM for
mycobacterial immunomodulation was since confirmed by inde-
pendent laboratories [14–17]. In the present study, we report on
the in-depth genomic and transcriptomic analysis of the sapM::
Tn BCG mutant, to assess which alterations are induced by the
transposon insertion in the sapM locus.
One of the major impediments to TB vaccine development is the
incomplete understanding of the mechanisms of protective immu-
nity against M.tb, so far obstructing rational vaccine development
[18]. Research on animal models and ongoing clinical trials may
reveal markers that correlate with a vaccine’s protective potential.
However, as long as we lack these correlates, vaccine design will be
challenging. One general idea that dominated immunology of
infectious diseases over the last decades, is the T helper type 1/-
type2 (Th1/Th2) paradigm. Following this model, Th1 cells would
protect the host from intracellular pathogens, like M.tb. Indeed,
the early appearance of Th1 type CD4+ T cells secreting IFNc is nec-
essary for the orchestration of protective immunity in the infected
lung [19]. However, controversy has arisen about whether the
quantitative extent of IFNɣ production in recall experiments has
value as a correlate of vaccine-induced protection against TB.
Indeed, several reports show that other anti-tuberculosis CD4
T-cell effector functions are at play [20–24].
In this evolving context, we also report on the safety in immuno-
compromised mice as well as rapid innate control over the sapM::
Tn vaccine bacteria, with intriguing impact on the induced adaptive
immunity. Our findings suggest that a live attenuated TB vaccine
that behaves more like an acute, rapidly immune-controlledFig. 1. Whole genome resequencing of the WT BCG Pasteur 1721 strain and of the sap
for both strains. The red square marks the TA dinucleotide site where the transposon is
figure legend, the reader is referred to the web version of this article.)infection, rather than the protracted chronic infection caused by
the current BCG vaccine, may yield an immune status that affords
more prolonged control of a subsequent TB infection.2. Results
2.1. In depth characterization of the sapM::Tn BCG versus WT BCG
strain
2.1.1. Whole-genome resequencing demonstrated very few
polymorphisms compared to the M. bovis BCG Pasteur reference
genome
The M. bovis BCG Pasteur strain 1721 [25], used to create the
sapM::Tn BCG mutant strain [13,26], differs from the 1173P2 Pas-
teur vaccine strain by a K43R point mutation in the rpsL gene (we
confirmed this by sequencing), conferring streptomycine resis-
tance, which is useful to avoid contaminations during the lengthy
and involved procedures in ordered transposonmutant library pro-
duction. To investigate whether there are any additional variants
between the WT BCG Pasteur and the sapM::Tn BCG mutant, we
performed a whole-genome resequencing analysis on both strains
(paired end 2  150 bp), mapping to the M. bovis BCG Pasteur
1173P reference genome, resulting in ±80x average coverage of
mapped reads (Suppl. Fig. 1). We could reconfirm the location of
the inserted Himar1 transposon, at the TA dinucleotide 8 bp before
the sapM start codon (Fig. 1). This was also demonstrated by de
novo assembly of the sequencing reads from the sapM::Tn BCG
mutant (data not shown). In addition, we performed a probabilistic
variant analysis on both WT BCG and sapM::Tn BCG mappings and
detected only minor modifications (single amino acid change) with
unknown impact. These variants are listed in Table 1 and were ver-
ified by Sanger sequencing. All variants versus the Pasteur refer-
ence are present in both the parental as well as the sapM::Tn
strains, with only one exception, i.e. the mutations in the sugI gene,
coding for sugar-transport integral membrane protein. The frame-
shift mutation (Indel S13fs) probably arose after the library prepa-
ration (in a later passage of the strain), since this frameshift
mutation is not present in sapM::Tn. The exact function of sugI is
unknown, however, it shows distant sequence similarity to glucose
permease GlcP of S. coelicolor and the galactose (GalP) and arabi-
nose (AraE) transporters of E. coli. Thus, the system is likely to
transport a monosaccharide [27]. It is described to be non-
essential in the H37Rv strain [28], which explains the absence of
phenotype in WT BCG due to the frameshift mutation. The single
nucleotide variant (SNV) in sapM::Tn BCG SugI (L44M) also likely
arose after library preparation since it is not present in WT BCG.M::Tn BCG mutant. Detailed representation of the read mappings at the sapM locus
inserted in the mutant strain. (For interpretation of the references to colour in this
Table 1
Variants detected in WT BCG and the sapM::Tn BCG disruption mutant. A probabilistic variant analysis was performed in CLC genome workbench on the reads mappings of both
the WT BCG and sapM::Tn BCG mutant strain. We observed only very few variations compared to the M. bovis BCG Pasteur str. 1173P2 reference genome. (SNV/
MNV = single/multiple nucleotide variants; Indel = insertions or deletions). The Tn insertion was picked up using de novo assembly of the sapM::Tn reads.
Illumina resequencing Sanger analysis
Position Mutation Type Gene AA change 1173P2 WT
(reference)
1721 BCG
WT
1721
SapM::Tn
1173P2
WT
1721 BCG
WT
1721
SapM::Tn
Variant 1 813,096 SNV rpsL K43R A G G A G G
Variant 2 1,344,671 MNV – – CG GC GC GC GC GC
2,764,157 SNV* BCG_2507c Synonymous T A A
Variant 3 3,197,940 InDel fadD26 L85fs – A A – A A
Variant 4 3,833,491 InDel** BCG_3499c A433InsA – CGC CGC
Variant 5 3,854,971 InDel cut3 G261Deletion
Insertion GR
– TCG TCG TCG TCG TCG
3,685,759 Tn insertion SapM promoter – – – tn –
Variant 6a 3,708,425 InDel sugI S13fs – A – – A –
Variant 6b 3,708,517 SNV sugI L44M C C A C C A
* Not verified by Sanger sequencing, because the mutation is synonymous.
** Sequencing did not work, due to the presence of repeats in the region of the mutation.
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during in vitro cultivation, as the three strains each have a different
sequence variant. Interestingly, both the parental as well as the
sapM::Tn strain contain a frame-shift mutation in the gene coding
for FadD26, a key enzyme in the biosynthesis pathway of the
phthiocerol dimycocerosate (PDIM) class of virulence lipids. This
fadD26 mutation is interesting from a vaccine engineering point-
of-view, as it further attenuates virulence [29,30].
2.1.2. The global transcriptional landscape in the sapM::Tn BCG
mutant strain is not significantly altered compared to WT BCG
Transcriptome analysis, by both RNAseq analysis and RT-PCR,
demonstrated that the sapM transcript is 20–50-fold reduced
compared to the WT BCG, while the transcription levels of other
genes remain largely unchanged (<2-fold change), except for a
10-fold upregulation of upp (encoding uracil phosphoribosyl-
transferase) which is immediately upstream of sapM in the gen-
ome, and a modest 2.4-fold downregulation of its downstream
gene (BCG_3376) (Fig. 2A–C, Suppl. Fig. 2A-B, Suppl. Table 1). Its
orthologue in M. smegmatis (msmeg_1684) and M.tb (rv3311) has
been described as a chaperone for the SecA2 protein export path-
way, with SapM being one of its substrates [31]. Six other genes
show a differential expression pattern (2-fold change) between
WT BCG and sapM::Tn, however, these expression differences are
small compared to the differences in expression of sapM and upp
(Suppl. Table 1). The transposon insertion thus only majorly affects
one nearby gene, and the changes in sapM and upp transcription
have almost no secondary effects on overall transcriptional regula-
tion. According to the Operon Correlation Browser on the TB Data-
base [32], the gene coding for SapM in M. tb (Rv3310) and the
downstream gene Rv3311 potentially form an operon. However,
in M. bovis BCG we see that transposon disruption of the sapM
upstream region in sapM::Tn BCG very strongly reduces the levels
of sapM transcript, while having a much more modest effect on the
levels of BCG_3376 (Rv3311 ortholog) transcription. These data
indicate that both genes are likely differentially regulated, ques-
tioning the idea of an operonic structure.
2.1.3. SapM protein is undetectable and secreted total phosphatase
activity is strongly reduced
As the SapM protein contains a 43 AA N-terminal signal
sequence and thus gets secreted in the culture medium, we col-
lected culture supernatant samples at various time-points.
First, we performed an ELISA on these supernatant samples
with a newly generated antibody directed against the recombinant
SapM protein produced in E. coli (Fig. 2D). While the amount ofSapM protein steadily increases over time of culture in the WT
BCG, the signal is nearly absent in the sapM::Tn BCG mutant sam-
ples for all time-points. We further confirmed the absence of full-
length SapM protein in the sapM::Tn BCG strain by SDS-PAGE and
western blotting in an independent experiment (Fig. 2E). We
detected a band of ±28 kDa in the WT BCG, but not in the sapM::
Tn BCG mutant sample. A smear is also detected above the
28 kDa band, which likely represents aspecific binding (as the pat-
tern appears to be identical for all samples). To check for any
remaining phosphatase activity in the culture medium, we per-
formed an in vitro phosphatase assay with p-Nitrophenyl phos-
phate (pNPP) as a substrate [33] (Fig. 2F). The measured in vitro
activity is significantly reduced for the sapM::Tn BCG mutant sam-
ple compared to WT BCG at early time-points. At later time-points
(day 8), we still observe a considerable signal, which is expected, as
the assay would also pick up activity of other phosphatases such as
the protein tyrosine phosphatases (PtpA and PtpB) [34].
Consequently, based on all of the data on this vaccine strain, we
concluded at this point that its improved vaccine efficiency must
indeed be due to a loss of function of SapM or the upregulation
of upp transcription, or both.
2.2 WT. BCG and sapM::Tn BCG demonstrate comparable in vivo safety
A requirement of live attenuated vaccines is that they should be
safe, even in immunocompromised hosts. Our previous analysis of
bacterial replication in immunocompetent Balb/c mice, infected
intravenously, did not show any difference between WT BCG and
sapM::Tn BCG [13]. The number of granulomas formed in livers
and lungs post-infection was unaffected [13]. To unambiguously
demonstrate safety of the sapM::Tn BCG mutant compared to WT
BCG in vivo, we investigated bacterial virulence in the absence of
adaptive immunity. Immunocompromised SCID mice, lacking both
T and B cells, were infected intravenously (i.v.) with a high (3x107
CFU) or lower dose (3x106 CFU) of both strains and survival was
monitored (Fig. 3). After both low and high doses, SCID mice
infected with sapM::Tn BCG mutant showed similar survival to
mice infected with WT BCG. Thus, in the SCID model, virulence
of sapM::Tn BCG is comparable to WT BCG.
2.3. At the lymph node draining the vaccination site, the sapM::Tn BCG
mutant is controlled faster than the WT BCG strain
Our previously reported observations indicated that vaccination
with the sapM::Tn BCG mutant triggered more effective recruit-
ment of iDCs into the draining lymph nodes (LNs) in Balb/c mice
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Fig. 3. | SapM::Tn BCG safety study in SCIDmice. Immunocompromised SCID mice
were infected intravenously with 3  106 versus 3  107 cfu of the WT BCG or
SapM::Tn BCG mutant and survival was monitored. (Log-rank test; WT BCG vs.
sapM::Tn; P = not significant). The control groups represent animals vaccinated with
PBS.
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induction of the innate immune response at early time points after
sapM::Tn BCG vaccination on the fate of the vaccine inoculum. To
enhance the validity, experiments were performed in F1 mice
(C57BL/6J  Balb/c) to assess robustness of the observed effects
to a more heterogeneous immunogenetic background [35]. After
subcutaneous (s.c) vaccination of F1 mice, less bacteria (50%)
were recovered from LNs of sapM::Tn BCG infected mice as com-
pared to WT BCG-infected mice at all time-points analyzed (i.e.
days 8, 14 and 28 post-infection) (Fig. 4A). It is clear that whereas
WT BCG could amplify from the inoculum, this was barely the case
for the sapM::Tn BCG mutant. Since differences are clear already
8 days post-vaccination, this result is most consistent with
improved control by innate immune mechanisms. Indeed, an anal-
ysis of intracellular survival of WT BCG and sapM::Tn BCG upon
infection of bone marrow derived macrophages (BM-DMs), showed
that WT BCG and sapM::Tn BCG are taken up similarly (as shown
before [13]) but that growth of the sapM::Tn BCG mutant is better
controlled compared to the WT BCG strain upon infection (Fig. 4B).
In line with these findings, such improved clearance of SapM-
mutated M.tb by BM-DMs has recently also been described [16],
an effect that was attributed to improved phagosomal maturation.
To further evaluate the impact of early innate growth control of
the bacteria, we have analyzed survival of sapM::Tn BCG and WT
BCG after intravenous infection of F1 mice. Twenty-four hours
post-infection, the bacterial load in the lungs and spleens from
mice that were infected with WT BCG was higher than the loads
of those infected with the sapM::Tn BCG mutant (50%) (Fig. 4C).
Three weeks post-infection, the difference was still observed in
the lungs, but not in the spleens. Similar results were obtained in
the spleen of C57BL/6J mice (Suppl. Fig. 3A), but not in the lungs
(data not shown). Cytokine levels were analyzed in the serum of
i.v. exposed mice at different time-points (6 h, 24 h, 48 h post-
vaccination), and significantly higher levels of IL1-b and IL17 could
be measured 24 h post-sapM::Tn BCG vaccination compared to WT
BCG vaccination (Suppl. Fig. 3B). In view of this early time point
post-vaccination, both IL1-b and IL17 are produced by innate
immune cells. These particular cytokines are known to be impor-
tant innate cytokines for bacterial killing, particularly in mycobac-
terial infection [36,37], which is consistent with the reduced
sapM::Tn BCG bacterial load.
2.4. Complementation of the sapM::Tn mutation reverses the
phenotypes.
As the Tn insertion in the sapM locus caused both a loss of func-
tion of sapM and a strong upregulation of the upstream upp gene,
we assessed whether the improved early innate growth control
of the sapM::Tn BCG bacteria was due to the loss of function of
SapM or the upregulation of upp transcription. For this purpose,3
Fig. 2. (A) Volcano plot comparing the sapM::Tn BCG mutant and the WT BCG. Genes
reads at the SapM locus in the WT BCG vs sapM::Tn BCG condition. Only one rep
BCG_3375 = sapM. (C) RT-PCR analysis of the sapM locus. RNA was prepared of cultures
BCG. An RT-PCR on the cDNA using primer sets directed against the sapM gene (blue bar
bars, respectively). The data presented here are averages (±SD) of the three biological rep
levels in the WT BCG strain (grey dotted line set at an average relative quantity of 1). The
levels of each target in the mutant strain to the same target in theWT BCG. Exact p-values
mutant and WT BCG 1721 were grown in 7H9 medium and supernatant samples were
polyclonal antibody. (E) SDS-PAGE and western blotting of WT BCG and sapM::Tn BCG m
OADC and supplemented with glucose only. The blots were developed with the anti-
sequence) is ±28 kDa in size and is only present in the WT BCG strain (black arrow). (F)
check the activity of the SapM enzyme. The plotted data for both ELISA and phosphata
signal induced by sterile 7H9 medium supplemented with 10% OADC. (For interpretatio
version of this article.)we have complemented the sapM::Tn BCG mutant strain with
the sapM gene under control of its own promotor. The sapM
expression is reverted to wild type levels in this sapM::Tn:compl
BCG mutant, but upp levels are still increased similarly as in the
sapM::Tn BCG mutant as demonstrated by RT-PCR analysis
(Fig. 5A). Protein analysis by ELISA and Western blot (Fig. 5B and
C) also demonstrated that SapM protein levels reverted to wild
type levels in the sapM::Tn:compl BCG mutant. Phosphatase activ-
ity was not completely restored in the supernatant of the sapM::
Tn:compl BCG mutant (Fig. 5D), but was majorly increased com-
pared to the phosphatase activity measured in the sapM::Tn BCG
mutant. Analysis of bacterial load in the draining LNs from mice
that were subcutaneously infected with either sapM::Tn:compl
BCG mutant, sapM::Tn BCG or WT BCG, showed that complemen-
tation of sapM expression partly restored WT phenotype
(Fig. 6A). By determining bacterial load in the lungs and spleens
frommice that were intravenously infected with either of the three
strains, we could also show that complementation of sapM expres-
sion could obliterate the sapM::Tn BCG mutant phenotype of
reduced bacterial load early post-infection (Fig. 6B, upper panels).
Since bacterial loads reach similarly lower levels at 3 weeks post-
infection (i.v.), the results show that SapM is mostly important
for control of bacterial growth at early time points post-infection.
These data also confirm that the observed phenotypes are due to
the reduced expression of sapM and not because of upregulation
of upp because upp expression is the same in sapM::Tn BCG and
the sapM::Tn:compl BCG mutant.with a > 2-fold change and a p-value <0.001 are depicted in red. (B) Mapped (sense)
licate of both WT BCG and sapM::Tn BCG samples is depicted. BCG_3374c = upp,
of biological triplicates of the sapM::Tn BCG disruption mutant, as well as of the WT
) and the directly up- and downstream genes (upp and BCG_3376, orange and green
licates. For each mutant, the targets are individually normalized to the transcription
* indicates significance (p < 0.05) by a two tailed t-test comparing the transcription
are given in the figure. (D-F) SapM protein and activity analysis. The sapM::Tn BCG
collected on various time points (D6 (Day 6) – D15). (D) ELISA using an anti-SapM
utant supernatant samples collected on day 15 and grown in 7H9 medium without
SapM antibody. The processed SapM protein (=removal of the N-terminal signal
In vitro phosphatase assay using p-Nitrophenyl phosphate (pNPP) as a substrate to
se assay are averaged over 2 technical replicates and corrected for the background
n of the references to colour in this figure legend, the reader is referred to the web
Fig. 4. In vivo and in vitro replication analysis: sapM::Tn BCG versus WT BCG. (A) F1 mice (Balb/c  C57BL/6J) were vaccinated s.c. with the WT BCG or sapM::Tn BCG
(2  106 cfu, 10 mice/group). At day 8, 14 and 28 post-infection, mice were sacrificed and the number of bacteria in the draining LNs was determined by cfu plating (Mann-
Whitney test; ** P < 0.01). (B) BM-DMs were infected with WT BCG or sapM::Tn BCG (MOI 10:1) for 4 h. Cells were washed and bacterial uptake was determined 4 h post-
infection. Bacterial replication was analyzed by cfu plating 24, 48 and 72 h, 6 days post-infection. (C) F1 mice were vaccinated i.v. with the WT BCG or sapM::Tn BCG (2  106
cfu, 8 mice/group). At 24 h and 3 weeks post-infection, mice were sacrificed and the number of bacteria in the spleens and lungs was determined by cfu plating (Mann-
Whitney test; ** P < 0.01).
3544 N. Festjens et al. / Vaccine 37 (2019) 3539–35512.5. Faster kinetics of iDC recruitment to lymphoid organs and
decrease in IFNc-producing CD4+ and CD8+ T recall response in sapM::
Tn BCG vaccinated mice compared to WT BCG vaccinated mice
We then further analyzed how improved innate control over
vaccine bacteria changes the immune response to the vaccine.
Hereto, we have vaccinated C57BL/6J mice s.c. with WT BCG or
sapM::Tn BCG mutant. At different time points, mice were sacri-
ficed and LNs and spleens were isolated. DC phenotyping was per-
formed. Significant differences were observed in total leukocyte
numbers and iDC recruitment kinetics after sapM::Tn BCG versus
WT BCG vaccination. In general, we observe a faster induction of
the innate immune response, reflected by a faster recruitment of
innate inflammatory cells to the secondary lymphoid organs
(dLN-spleen), and by a faster contraction of the innate immune
response, seen by lower leukocyte cell numbers at day 14 post-vaccination with sapM::Tn BCG (Fig. 7). Next, T cell immunity
was assessed by restimulation of splenocytes or LN cells with
either the mycobacterial antigen Ag85A, the M.tb extract PPD or
by anti-CD3/28, a stimulus that activates all T cells, as a control.
Vaccination with sapM::Tn BCG leads to a lower number of lymph
node and spleen IFNc-producing CD4+ (Th1) and CD8+ (Tc1) T cells
2 weeks post-vaccination compared to WT BCG (Fig. 8A). After vac-
cination with a lower dose, this observation is only seen for Tc1
cells, following polyclonal stimulation in the LNs and spleen
(Suppl. Fig. 4). IFNc measurements in the supernatant following
stimulation with the different antigens also demonstrated lower
levels of IFNc in the sapM::Tn BCG condition (Fig. 8B). These lower
numbers of IFNc-producing CD4+ and CD8+ T cells were seen at
early time points (2 weeks post-infection), but the difference
became non-significant at later time points (Suppl. Fig. 5), consis-
tent with the hypothesis that a fast innate control of bacterial load
Fig. 5. RT-PCR analysis of the sapM locus and SapM protein and activity analysis in the sapM::Tn:complementation mutant versus WT BCG. (A) RNA was prepared of
cultures of biological triplicates of the sapM::Tn BCG disruption mutant (red), the WT BCG (black) and the sapM::Tn:complementation BCG mutant (green). An RT-PCR on the
cDNA used primer sets directed against the sapM gene (sapM b primers - left panel) and the directly upstream gene upp (upp2 primers - right panel). The data presented here
are averages (±SD) of three technical replicates. For each mutant, the targets are individually normalized to the transcription levels in the WT BCG strain (grey dotted line set
at an average relative quantity of 1). The * indicates significance (p < 0.05) by an ANOVA test (Tukey post-hoc), comparing the transcription levels of each target in the 3
different strains. Exact p-values are given in the figure. (B-D) The sapM::Tn BCG mutant, WT BCG 1721, sapM::Tn:complementation BCG mutant and sapM::Tn:empty vector
were grown in 7H9 medium and supernatant samples were collected on various time points (D1 (Day 1) – D15). (B) ELISA using an anti-SapM polyclonal antibody. The
plotted data for both ELISA and phosphatase assay is averaged over 2 technical replicates and corrected for the background signal induced by sterile 7H9 medium
supplemented with 10% OADC. (C) SDS-PAGE and western blotting of indicated supernatant samples collected on day 10 and grown in 7H9 medium without OADC and
supplemented with glucose only. The blots were developed with the anti-SapM antibody. The processed SapM protein (=removal of the N-terminal signal sequence) is
±28 kDa in size and is only present in the WT BCG strain and sapM::Tn:complementation mutant. (D) In vitro phosphatase assay using p-Nitrophenyl phosphate (pNPP) as a
substrate to check the activity of the SapM enzyme. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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response after sapM::Tn BCG vaccination. The sapM::Tn BCG vac-
cine thus behaves like a rapidly (though not completely) controlled
bacterial infection, contrary to WT BCG, which expands and causes
a more protracted infection at the vaccination site.
3. Discussion
Our former research demonstrated that an M. bovis BCG sapM::
Tn mutant led to enhanced long-term survival of vaccinated mice
challenged with TB [13]. Further development of this TB vaccine
candidate requires further characterization of the mutant and its
safety, which was the main purpose of the extensive work pre-
sented in this study.
We have performed a whole genome resequencing-based vari-
ant analysis of this sapM::Tn BCG mutant, as well as of its parent
BCG strain [25], using a shotgun Illumina sequencing approach.
Very few polymorphisms could be detected compared to the M.
bovis BCG Pasteur reference genome, most of which were already
present in the streptomycin-resistant Pasteur derivative in which
we designed our transposon mutant. A frame-shift mutation hadinactivated the gene coding for FadD26, a key enzyme in the
biosynthesis pathway of the PDIM class of virulence lipids that
are involved in hiding M. tb’s own PAMPs from the host’s innate
immune system [29]. Knocking out this gene in M. tb severely
impairs the pathogen’s ability to survive in vivo [29,30]. For this
reason, the fadD26 gene is deleted in MTBVAC, the first live-
attenuatedM. tb vaccine [38]. Chen et al. compared PDIM/PGL pro-
duction in 12 different M. bovis BCG substrains and found that
while most were PDIM-positive (including BCG Pasteur), three of
these strains, BCG Japan (or Tokyo), Moreau and Glaxo, do not pro-
duce this class of lipids [39]. The authors further reported that
there was a correlation between the virulence that was associated
with the BCG substrains and their lipid profile: the on average
more virulent, PDIMs/PGLs-producers and the on average less vir-
ulent, PDIMs/PGLs non-producers. In a later study it was shown
that the PDIM-defect in BCG Moreau was due to a deletion in the
FadD26 and the directly downstream ppsA gene in the same
operon, which is also involved in the PDIM/PGL lipid biosynthesis
pathway [40]. The authors reported that this locus was intact in
BCG Japan and Glaxo. Naka et al later showed that BCG Tokyo
172 is actually divided into two subpopulations, in which type II,
Fig. 6. In vivo replication analysis: sapM::Tn BCG versus sapM::Tn:complementation BCG versus WT BCG. (A) C57BL/6J mice were vaccinated s.c. with the WT BCG, sapM::
Tn BCG or sapM::Tn:complementation BCG (2  106 cfu, 6 mice/group). At day 8, 14 and 28 post-infection, mice were sacrificed and the number of bacteria in the draining LNs
was determined by cfu plating (Mann-Whitney test; ** P < 0.01). (B) C57BL/6J mice were vaccinated i.v. with the WT BCG, sapM::Tn BCG or sapM::Tn:complementation BCG
(2  106 cfu, 7–8 mice/group). At 24 h and 3 weeks post-infection, mice were sacrificed and the number of bacteria in the spleens and lungs was determined by cfu plating
(Mann-Whitney test; ** P < 0.01).
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Fig. 7. iDC recruitment to lymphoid organs starts earlier when mice are
vaccinated with the BCG sapM::Tn BCG strain. C57BL/6J mice were immunized s.c.
at the base of the tail (2  106 cfu, 5–10 mice/group (A-B); 2.105 cfu, 10 mice/group
(C-D)) with WT BCG or sapM::Tn BCG mutant. Seven and 14 days later, the mice
were sacrificed, and inguinal LNs, brachial LNs and spleens were isolated. Cells were
prepared, labelled with different antibodies staining DCs and analyzed by flow
cytometry. Total cell numbers (A, C) and the kinetics of iDC (CD103+MHCIIhi CD11b+
Ly6C+) recruitment (B, D) differ upon BCG sapM::Tn BCG and WT BCG vaccination.
(Mann-Whitney; *P < 0.05, **P < 0.01).
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does not produce PDIM lipids [41]. It is unclear whether this strain
is the same as the Japan strain that was earlier reported to lack
PDIMs [39]. As the Japan/Tokyo, Moreau and Glaxo substrains are
not derived from one another [42], and as we have here detected
a fadD26 frameshift in a substrain derived from BCG Pasteur, these
independent mutations in genes coding for key enzymes in the
PDIM/PGL lipid biosynthesis pathway indicate that there may be
a selective force in favor of losing this class of lipids during
in vitro BCG cultivation. We also conclude that, as our strain has
this background fadD26 mutation, the sapM::Tn vaccine strain in
our studies is in fact a fadD26/sapM::Tn double mutant, which is
important knowledge for further development, as it shows that
the sapM mutation improves vaccine efficacy even in this fadD26
background, as is currently being used for safety enhancement of
the MTBVAC lead clinical TB vaccine candidate. In addition to our
sapM::Tn BCG mutant, this FadD26 mutation will almost certainly
also be present in the Zmp1 BCG mutant candidate vaccine that
was described in [43], since it is also derived from the M. bovis
BCG Pasteur 1721 strain.
By comparative transcriptome profiling between WT BCG and
sapM::Tn BCG, we observed an almost complete absence of sapM
transcript in the mutant strain, together with a significant upregu-
lation of sapM’s upstream gene upp. By RNAseq analysis, we further
showed that the global transcriptional landscape in the sapM::Tn
BCG mutant strain is not significantly altered compared to the WT
BCG.
The most promising strategy for improved TB vaccines cur-
rently is the development of an improved attenuated live vaccine,
either used alone or in combination with subunit booster vaccines[6]. Furthermore, re-vaccination with BCG in adolescence has
recently shown promise as well [44]. An improved version of the
BCG vaccine could thus be valuable in this context too. However,
working with live vaccines encompasses potential safety issues,
especially since a high incidence of HIV is found in areas where
TB is endemic. A novel vaccine candidate should therefore be at
least as safe as BCG. Safety of the sapM::Tn BCG strain was tested
in immunocompromised SCID mice, in comparison with the WT
BCG. Survival time upon infection of the mice was similar for both
strains, at both high and low infectious doses, demonstrating com-
parable safety of the sapM::Tn BCG strain and WT BCG.
Due to the lack of natural infection-induced protection, the type
of immune response that is crucial in preventingM.tb infection and
TB, and which therefore should be induced by vaccination, remains
largely unknown. At present, it is believed that a particular balance
between differentially polarized adaptive immune responses is
crucial to overcome a TB infection. M. tb as well as M. bovis, from
which BCG derives, have evolved immunomodulatory mechanisms
to perturb this balance to its own benefit [45,46]. We and others
propose that an improved, live attenuated vaccine will need to
be engineered to take down these immunomodulatory virulence
factors from the pathogenic parental Mycobacteria from which
these vaccines (incl. BCG) have been derived, and we propose that
the SapM secreted phosphatase is such a factor. Our results
demonstrate a better innate control of sapM::Tn BCG vaccine bac-
teria as compared to WT BCG upon vaccination, correlating with a
faster influx of iDCs in lymphoid organs draining the vaccination
site, and more modest primary expansion of TB-antigen-specific
IFNc-producing CD4+ and CD8+ T cells. Since we did not further
define subsets of responding cells (such as expressing markers
associated with antigen exposure, e.g. KLRG-1, PD-1, CD62L,
CD44, CCR7 [47] or expressing other cytokines, e.g. TNFa, IL-17,
FoxP3,. . .), we cannot further subtype the T cells responding to
the specific antigens used, limiting our conclusions to the effect
on Th1/Tc1 cells. Further study will be performed to investigate
adaptive immune responses more in depth. Both WT BCG and
sapM::Tn BCG have equivalent growth characteristics during
in vitro cultivation (Suppl. Fig. 6), excluding that mere growth rate
differences could have caused any difference in abovementioned
phenotypes. Since complementation of sapM expression abolished
the improved growth control of the sapM::Tn BCG mutant upon
infection, the observed phenotypes are specifically due to the
reduced expression of sapM. To conclude, all of this shows that
the sapM mutated BCG vaccine behaves like a more immediately
effectively controlled bacterial infection as compared to WT BCG.
Importantly, in the context of viral infections, it has been well
established that a protracted fight of the immune system to a
chronic infection yields poorly efficacious memory due to poor
generation of central memory T cells [48]. Possibly, the same holds
true for chronic bacterial intracellular infections, of which BCG vac-
cination is an example, a hypothesis which will need to be proved
by future research. Together with the comparable safety of the
SapM-mutated BCG and WT BCG in immunodeficient mice, and
the fact that the sapM::Tn BCG vaccine is presently one of the
few priming vaccines for which enhanced long-term survival of
TB-infected animals has been demonstrated [13], these results
warrant inclusion of the SapM inactivation strategy in future gen-
erations of live attenuated TB vaccines.4. Materials and methods
4.1. Mycobacterial strains and media
The streptomycin resistant M. bovis BCG Pasteur strain
1721 [25] (RpsL, K43R; a gift of Dr. P. Sander, Institute for Medical
Fig. 8. Vaccination with sapM::Tn BCG induces reduced frequencies of IFNc-producing CD4+ and CD8+ T cells compared to WT BCG. C57BL/6J mice were immunized s.c.
at the base of the tail with a high dose of WT BCG (black bars) or sapM::Tn BCG mutant (red bars) (2  106 cfu, 5 mice/group). 14 days later, the mice were sacrificed, and
inguinal LNs, brachial LNs and spleens were isolated. Cells were prepared and the T cell response was analyzed by intracellular cytokine staining followed by flow cytometry
(A). Additionally, supernatants of stimulated spleen cells and controls were harvested 48 h post-stimulation and IFNc concentration was determined by bioplex (B). (Mann-
Whitney or 2way ANOVA; *P < 0.05, **P < 0.01). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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[13] were grown in shaking culture flasks in Middlebrook 7H9
broth (Difco) supplemented with 0.05% Tween80 and Middlebrook
Oleic Albumin Dextrose Catalase (OADC, Becton Dickinson) when
grown in liquid culture. Difco Middlebrook 7H10 agar was used
for growth on solid culture. For the SDS-PAGE and western blotting
experiment, M. bovis BCG cultures were grown in 7H9 medium
without OADC, but supplemented with 0.2% glucose, 0.2% glycerol
and 0.05% of Tween80. All strains were frozen as 1 mL cultures at
OD600 1 in 20% glycerol (final concentration). For all in vitro and
in vivo infections described in this paper, cells were started from
a glycerol stock, grown in shaking culture flasks (OD600 always  1)
as described above, subcultured once and further grown until
OD600  0.8 after which cells were collected and prepared for infec-
tion. For each experiment, we confirmed that we immunized with
the same number of viable CFU by CFU plating of the inoculum.4.2. Whole genome Illumina resequencing and data analysis
Genomic DNA of the M. bovis BCG strain 1721 and its sapM::Tn
BCG mutant (Tn-7432) was prepared [49] and used for an Illumina
library prep (Nextera XT DNA Library Preparation kit). The libraries
were sequenced on an Illumina MiSeq instrument (2  150 bp
reads), with an average 80x coverage per genome. The library prep
and sequencing was performed by the VIB Nucleomics Core facility
(www.nucleomics.be). The data was analyzed by the VIB Nucle-
omics Core facility and the VIB Bioinformatics Core facility
(www.bits.vib.be) using CLC Genomics Workbench [50]. All reads
were processed using the standard CLC-GWB settings (Details in
Suppl. Methods).4.3. RT-qPCR analysis
10 mL ofM. bovis BCG cultures (grown in standard 7H9 medium
until an OD600 of 0.8 – 1.0) were centrifuged and the pellets were
washed once with 0.5% Tween80 solution in PBS. RNA was pre-
pared as described in [51] with minor changes (Suppl. Methods).
cDNA was prepared from 1 lg of DNase-treated RNA using the
iScript Synthesis Kit (BioRad) and a control reaction lacking reverse
transcriptase was included for each sample. The RT-PCR program
was as follows: 10 min at 25 C, 30 min at 42 C, 5 min at 85 C,
and cooling down to 12 C. Real time quantitative PCR was done
on a LightCycler 480 (Roche Diagnostics) using the SensiFast
SYBR-NoRox kit (BioLine), in triplicate for each cDNA sample, on
a 384-multiwell plate, with 1 ng of cDNA in a total volume of
10 lL. Details in Suppl. Methods.4.4. RNA-Seq analysis
M. bovis BCG cultures were grown in standard 7H9 medium in
triplicates until an OD600 of 0.8 – 1.0 and RNA was prepared as
described for the RT-qPCR analysis. This RNA was then depleted
of ribosomal RNA (Ribo-Zero rRNA removal kit for gram-positive
bacteria) and the remaining RNA was prepared for Illumina
sequencing (TruSeq stranded total RNA preparation kit). This
library preparation takes into account the strandedness of the
RNA and is able to distinguish between sense and antisense tran-
scripts. The libraries were sequenced on an Illumina NextSeq500
(75 bp single-end). The library preparation and sequencing was
performed by the VIB Nucleomics Core facility. The data was ana-
lyzed using the standard RNA-seq analysis workflow in CLC Geno-
mics Workbench v7 [50] (Details in Suppl. Methods).4.5. Laboratory animals
Female C57BL/6J mice (Janvier), C57BL/6J  Balb/c mice (F1,
Harlan) and CB-17 SCID mice (Charles River) were housed under
specific pathogen-free conditions in micro-isolator units. At the
beginning of the experiment, the mice were 7–8 weeks old. All
experiments were approved by and performed according to the
guidelines of the ethical committee of Ghent University, Belgium.
4.6. SCID safety study
Eight-week-old female CB-17 SCID mice (Charles River Labora-
tories, 7 or 8 mice/group as indicated) were immunized intra-
venously via tail vein injection with 100 lL (3  106 versus
3  107 cfu) of WT BCG Pasteur or sapM::Tn BCG mutant (diluted
in PBS). The control group received PBS (pH 7.5). The animals were
observed and weighed initially on a 2-weekly basis and from day
82 post-infection on, every 2 days (until day 201 post-infection).
The differences of time to survival between the different groups
were compared using log-rank test. Weight loss of 20% of initial
body weight was set as the ethical endpoint.
4.7. Vaccination with M. bovis BCG
At the age of 8 weeks, female mice were infected s.c. or i.v. with
WT BCG or sapM::Tn BCG mutant in PBS. At different time points
post-infection, mice were sacrificed and organs removed asepti-
cally for further processing and either analysis of CFU counts or
DC and T cell phenotyping and antigen-specific cytokine determi-
nation (details in Suppl. Methods).
4.8. Statistical analysis
Results are presented as means ± standard error of the mean
(SEM) unless otherwise stated and groups were compared using
statistical tests as mentioned in the text, using Prism Software
(GraphPad Software, San Diego, CA).
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